Compare Bristol-Myers Squibb Co (BMY) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Zillow Group Inc Class A — how do they compare? Bristol-Myers Squibb Co trades at $58.6 (market cap $116.30B), while Zillow Group Inc Class A trades at $33.57 (market cap $7.28B). The key difference: Bristol-Myers Squibb Co is far larger — about 16× Zillow Group Inc Class A's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals.
| BMY | ZG | |
|---|---|---|
Market Cap | $116.30B | $7.28B |
Sector | Health | Media |
52-Week High | $62.37 | $86.76 |
52-Week Low | $42.60 | $29.14 |
Enterprise Value | $152.24B | $6.93B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Zillow Group (ZG) trades at $31.94, down 0.19% with a bearish technical signal. The company shows improving fundamentals with revenue growth to $2.58B in 2025 and a return to profitability with $23M net income. Analyst consensus remains positive with a $57.80 price target, though recent securities class action lawsuits create near-term uncertainty. Technical indicators show the stock trading near support at $31 with resistance at $33.
ZG presents a mixed outlook with strong analyst support but significant legal overhangs. The company's turnaround to profitability and 51% buy rating suggest upside potential, but ongoing litigation regarding anticompetitive practices with Redfin poses substantial risk. Investors should weigh improving fundamentals against regulatory and legal challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
